Abstract
Purpose: To assess the acceptance, long term efficacy and preference of Sildenafil in impotent patients previously on auto-intracavernosal therapy.
Material and methods: The patients were the 107 men (mean age 58.4 y) on auto-intracavernosal therapy (auto-IC) for more than 6 months (mean duration 32.7 months >12 months in 100) who were consecutively seen within 6 months of the launch of Sildenafil in France. If there was no contra-indications to Sildenafil they were proposed a trial of Sildenafil at home. Following this trial they were given the possibility to change their therapy and were followed for 1 y at 3 months intervals.
Results: Three patients had contra-indications to Sildenafil. Of the remaining 104, 45 (43%) refused the trial, mainly because they were afraid of possible cardiac risks (n=21, including 51% of the psychogenic and mixed patients compared to 8% of the predominantly organic ones). Among the 59 who tried it, Sildenafil gave good results in 46 (78%), including 100% of the predominantly psychogenic and 61.5% of the predominantly organic ones) with minimum effective doses of 25 mg in 7, 50 mg in 18 and 100 mg in 21. It failed in 9 (15%) and gave average results in 4 (penetration with a non fully satisfying erection). There was a clear relationship between the sensitivity to Sildenafil and that to Alprostadil, the vasoactive agent predominantly used for the auto-ICIs. Every 46 patients with good result of Sildenafil elected to continue with this drug, including 3 who used both Sildenafil and auto-ICIs in alternance. Every 4 patients with average results elected to continue with auto-ICI including 1 who also used Sildenafil in alternance. Five of the 50 patients with good or average results were lost to follow-up within 6 months. At the 1 y follow-up visit, 43 of the 45 others were still using Sildenafil, in alternance with auto-ICI in 1. No one reported a decrease in efficacy with time. The 2 patients with average results still in the study were on auto-ICIs.
Conclusion: Sildenafil is highly effective in the impotent men previously treated with auto-ICI and its efficacy is maintained at least for 1 y. When tried and effective it is preferred by most men but almost half of our patients refused trying it.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Krane R, Brock G, Eardley I, Fourcroy J, Giuliano F, Hutter A, Teloken C, Vickers M . Oral non endocrine treatment In: Proceedings of the 1st International Consultation on Erectile Dysfunction, July 1–3, 1999, Paris, Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R eds. Erectile Dysfunction Health Publication Ltd 2000 pp 243–303.
Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH . Clinical safety of oral Sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction Int J Impot Research 1998; 10: 69–74.
Hatzichristou D, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A . Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year J Urol 2000; 164: 1197–1200.
McMahon C, Samali R, Johnson H . Efficacy, safety and patient acceptance of Sildenafil citrate as treatment for erectile dysfunction J Urol 2000; 164: 1192–1196.
Giuliano F, Montorsi F, Mirone V, Rossi D . Sweeney M for the Sildenafil multicenter study group. Switching from intracavernous prostaglandine E1 injections to oral Sildenafil citrate in patients with erectile dysfunction: results of a multicenter european study J Urol 2000; 164: 708–711.
Sadovsky R, Miller T, Moskowitz M, Hackett G . Three-year update of Sildenafil citrate (Viagra®) efficacy and safety Int J Clinical Practice 2001; 55: 115–128.
Shabsigh R, Padma-Nathan H, Gittleman M, Mc Murray J, Kaufman J, Goldstein I . Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra) Urology 2000; 55: 477–480.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buvat, J., Lemaire, A. & Ratajczyk, J. Acceptance, efficacy and preference of Sildenafil in patients on long term auto-intracavernosal therapy: a study with follow-up at one year. Int J Impot Res 14, 483–486 (2002). https://doi.org/10.1038/sj.ijir.3900913
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3900913
Keywords
This article is cited by
-
Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction
International Journal of Impotence Research (2007)
-
Significance of hypogonadism in erectile dysfunction
World Journal of Urology (2006)
-
Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders
International Journal of Impotence Research (2005)